Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
Daniel Chille So we can now induce hypoxia like conditions in our injured population or even within our athletes with blood flow restriction training or putting on kind of a mask to simulate altitude, which drives this erythropoiethe and more blood cells which has a net positive on performance and ability to utilize less oxygen
Results are gradual and depend on consistency
Whereas most mitochondrial respiratory chain disorders are hardly amenable to treatments, oral coenzyme Q 10 supplementation has been shown to improve muscular symptoms in some (yet not all) patients with primary coenzyme Q 10 deficiency (10)